News

Morbidities linger at least 20 years for young adult cancer survivors


 

References

Survivors of young adult cancers had 1.5 times more hospitalizations than did controls in a population-based study spanning 20 years, Dr. Devon P. Richardson and coauthors at the University of Toronto reported online in the Journal of Clinical Oncology.

Investigators compared a cohort of 20,275 patients enrolled in the Ontario Cancer Registry who were aged 20-44 years at the time of diagnosis, and had survived at least 5 years cancer free, with 101,344 noncancer controls selected from a roster of all individuals eligible for the Ontario Health Insurance Plan. Over one-third of survivors were hospitalized during the 20-year study period, and the adjusted relative rate (ARR) of hospitalizations, compared with controls, was 1.51 (95% confidence interval, 1.48-1.54). Hospitalization rates were highest in survivors of upper GI cancers (ARR, 2.49), leukemia (ARR, 2.23), and urologic (ARR, 2.20) cancers, the investigators reported.

In the first three follow-up periods (5-8, 9-11, and 12-14 years after diagnosis), the hospitalization rate in survivors (per 100 person-years) stayed constant at 0.22, whereas the rate decreased significantly in the last two time periods: 0.17 at 15-17 years and 0.15 for 18-20 years after diagnosis (P <.0001). The hospitalization rate among controls was relatively constant during the entire time period, ranging from 0.12 to 0.14, they said.

“The results of our study show that 5-year survivors of cancer diagnosed during young adulthood will have morbidities that increase the number of hospitalizations in this cohort compared with control subjects for at least 20 years after diagnosis,” the authors wrote.

Read the full article here: J. Clin. Oncol. 2015 July 13 (doi:10.1200/JCO.2014.60.1914).

Recommended Reading

Measuring end-of-life care in oncology practices: learning from the care of the dying
MDedge Hematology and Oncology
Cardiovascular disease in oncology
MDedge Hematology and Oncology
Obesity, genetic variations found in adult survivors of childhood cancer
MDedge Hematology and Oncology
ASCO plumbs the value of new cancer therapies
MDedge Hematology and Oncology
Urea cream bests antioxidant ointment to prevent chemo-induced hand-foot syndrome
MDedge Hematology and Oncology
Faster ipilimumab infusion for solid cancers proves safe
MDedge Hematology and Oncology
Naloxone lotion improves disabling itch in CTCL
MDedge Hematology and Oncology
Hospital clinicians commonly work while sick
MDedge Hematology and Oncology
Adolescent cancer survivors report more emotional, neurocognitive impairment than do siblings
MDedge Hematology and Oncology
High VTE recurrence risk persists for at least 3 years
MDedge Hematology and Oncology